Drug Trial Radar · NCT05748873
Promising ROd-cone DYstrophy Gene therapY
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Actual
Start
Apr 12, 2023
Primary completion
Feb 2027
Study completion Feb 2031
Sponsor
- Lead sponsor
- SparingVisionIndustry
- Sponsor type
- Industry
- First posted
- Mar 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).
Conditions
- Retinitis Pigmentosa
Interventions
SPVN06Drug
AAV-RdCVF-RdCVFL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD, 12 months after administration of gene therapy.Time frame: Baseline to 12 months after administration of gene therapy
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Bascom Palmer Eye Institute/University of Miami
Miami, Florida
Mass Eye and Ear
Boston, Massachusetts
Casey Eye Institute
Portland, Oregon
UPMC Eye Center
Pittsburgh, Pennsylvania
Retina Foundation of the Southwest
Dallas, Texas
CHNO XV-XX Paris - CIC 1423
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.